Abstract: The invention is the combination or combined use of (i) a compound able to disrupt or impede netrin-1/netrin-1 receptors interaction or netrin-1-mediated receptor dimerization, also called herein a NTN1 neutralizing agent, which compound may be an antibody binding to netrin-1 or anti-netrin-1 antibody, and (ii) an immune checkpoint inhibitor, in the treatment of cancer. The composition may comprise an anti-netrin-1 antibody and an immune checkpoint inhibitor, for use as an anticancerous drug with a simultaneous, separate or sequential administration of the anti-netrin-1 antibody and the immune checkpoint inhibitor to a patient.

Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.

Abstract: A method for monitoring a hadron beam during hadron-therapy treatment of a subject including tumour cells labelled with a radiopharmaceutical product, in which the hadron beam includes a plurality of discrete hadron bursts, the method including the following steps: when a burst impacts on the subject, detecting the prompt gamma generated by the interaction of the hadrons of the burst with the tissues of the subject using a Compton telescope and reconstructing an image of the interaction volume; when no burst impacts on the subject, extracting the position of the tumour cells labelled with the radiopharmaceutical product using the Compton telescope and reconstructing an image of the total volume of the tumour; comparing the image of the interaction volume and the image of the total volume of the tumour so as to locate the measured interaction volume relative to the measured total volume of the tumour.

Abstract: A light-emission device includes at least one emission module comprising: a luminescent crystal known as a concentrator crystal with at least six faces which are parallel in pairs, including a first and a second face, known as lateral faces, perpendicular to a direction x and separated by a distance corresponding to a horizontal dimension of the concentrator in the direction x; a first mirror, which is configured such as to cover the first lateral face at least partly, defining a surface area covered by the first mirror, and at least one surface area (SFS1) which is not covered by the first mirror defining an associated output face; a second mirror, which is configured such as to cover at least 95% of the second lateral face; a brightness triggering element, which is designed to generate emission of brightness radiation (LF) in the luminescent crystal; a ratio R between the non-covered surface area (SFS1) and a surface area (SL) of the first lateral face being determined such that rays of the brightness radia

Abstract: The present invention [relates to] a regulation system (28) for a multi-active bridge converter (10) with hybrid supply, comprising: an input current port (20) comprising an H-shape switch bridge (30) having a switch (T1) controlled by a first law having a first duty cycle, at least one output voltage port (22, 24) comprising an H-shape switch bridge (38, 40), one switch (T 21, T 31) of which is controlled by a second law which is phase-shifted with respect to the first law, the regulation system (28) regulates the converter (10) to a setpoint comprising a setpoint current value for the current of the current port (20) and a setpoint voltage value for a voltage port (22, 24).

Abstract: The invention relates to an electrically insulating composite material (1) comprising a polyepoxide matrix (2) of cycloaliphatic type or of diglycidyl ether type in a content of less than 40% by mass, from 20 to 75% by mass of one or several micrometric and/or mesometric filler(s) (3), and from 0.1 to 20% by mass of at least one ionic liquid (4), the masses being expressed relative to the total mass of the electrically insulating composite material (1). The invention also relates to a method for manufacturing such an electrically insulating composite material (1), as well as its use for an electrically insulating support (9) in a metal-enclosed substation (5).

Abstract: The method is for the discriminant monitoring of a composite multi-material assembly (1) having at least one internal layer (10) made of a first, electrically conductive composite material and a second layer (11) made of a second, electrically insulating composite material, the second layer (11) covering the first internal layer (10).

Abstract: There is provided a system for generating a spectrogram signal representative of a spectrogram of an initial signal, the system comprising: a temporal phase modulator for receiving the initial signal and quadratically modulating a temporal phase of the initial signal in a periodic series of consecutive quadratic time lenses in order to obtain a temporal phase modulated signal; a spectral phase modulator for quadratically modulating a spectral phase of the temporal phase modulated signal to obtain a given signal representative of a series of consecutive spectra; and a sensor for detecting the given signal in a temporal domain in order to obtained a sensed signal and outputting the sensed signal, the sensed signal being representative of the spectrogram of the initial signal.

Abstract: A method and a system method for real-time wide-field dynamic temperature sensing of an object, the method comprising producing wide-field illumination to upconverting nanoparticles at the object plane, collecting a light emitted by the upconverting nanoparticles, dividing a collected light into a reflected component and a transmitted component, imaging the reflected component into a first image, imaging the transmitted component into a second image; processing the images; and reconstruction of the object from resulting proceed images.

Abstract: The present invention relates to a process for preparing aromatic acyl derivatives of formula (I) using methanesulfonic acid. The invention further relates to methods for preparing biological active ingredients. such as paracetamol.

Abstract: The present invention relates to a fusion peptide having one of the following formulae: P1-L-P2 (I) or P2-L-P1 (II) wherein P1 is chosen from the proline-rich antimicrobial peptides; Lisa peptide linker; and P2 has the following formula (III): wherein m is 0 or 1; n is an integer comprised between 0 and 9; p is an integer comprised between 0 and 10; r is 0, 1 or 2; s is 0 or 1; Gln is glutamine; R1 is the side chain of arginine or lysine; R2 is for example a —(CH2)—C3-6-cycloalkyl group optionally substituted; R3 is for example a C1-8-alkyl group; R4 is in particular a C1-8-alkyl group optionally substituted by a C3-6-cycloalkyl group; R5 is for example a —(CH2)—C3-6-cycloalkyl group; R6 is in particular —COOH, wherein, when the fusion peptide has the formula (II), its C-terminus contains a —CO— group engaged in a peptide bond with said linker.

Abstract: A magnetic tunnel junction includes at least one free layer, at least one reference layer, and at least one tunnel barrier separating the free layer and the reference layer, wherein the free layer is an inhomogeneous granular layer including at least two grains, each grain of the at least two grains being sensibly magnetically decoupled from the other adjacent grains of the at least two grains.

Abstract: A method for detecting a lytic activity of one or more types of phages or of the activity of one or more antibiotics with respect to a bacterial strain, the method including using a first multiwell plate, each well receiving a sample containing phages or antibiotics, making at least one deposit on a transparent area of a support, the deposit containing bacteria of the bacterial strain, applying the first plate against the support so that each sample in each well comes into contact with the deposit, for each well, determining, using the detection means, the activity or absence of activity of the phage or antibiotic with respect to the bacterial strain, taking into account the intensity of light signals transmitted through each well and/or the variation thereof over time.

Abstract: A compound of formula (I) or any of its pharmaceutically acceptable salt for use in the treatment and/or prevention of a RNA virus infection, and a RNA virus infection from group IV or V of the Baltimore classification wherein R3 represents a chlorine atom or a hydrogen atom, R represents a (C1-C4)alkyl group, a (C3-C6)cycloalkyl group, a halogen atom, a (C1-C5)alkoxy group, a —SO2—NRaRb group, a —SO3H group, a —OH group, a —O—SO2—ORc group or a —O—P(?O)—(ORc)(ORd) group, R1 represents (i) a CF3 group, (ii) a (C1-C10)alkyl group, (iii) a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group or (iv) a phenyl group or a naphthyl group, and R2 represents a hydrogen atom, a (C1-C10)alkyl group, a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group and further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.

Abstract: The invention relates to a synthetic sialoside presenting the formula (I): Neu5-Ac-?2-6-R1(R2)[GlcNAc?1-4]n-GlcNAc Formula wherein: -GlcNAc is N-acetylglucosamine; -GlcNAc?1-4 ia a N-acetylglucosamine unit linked with a ?1-4 link; -n is a superior or equal to 1; -R1 is a glycan structure comprising at least one galactose (Gal); and -R2 is chosen among the following groups: H, fucose linked with a ?1-3 link (Fuc?1-3) or a1-4 link (Fuc?1-4).

Abstract: A light emitting device including a plurality of light emitting diodes (LED) configured to emit an incident light; a solid luminescent concentrator (CL) of index nc including two parallel faces, called large faces (FE1, FE2), along an horizontal plane xy, and n?>2 faces called side faces (FL1, FL2, FL3, F4), at least one of the first and the second large face being illuminated by the incident light (Ld), the concentrator being configured to absorb the incident light (Ld) and then emit a luminescent light (LL), a portion of the luminescent light being guided by total internal reflection (Lg) in the concentrator and passing through a first so-called exit face of the concentrator (FL1) in contact with an exit medium (EM) of index ns<nc, and forming an exit beam; a cooling system (CS) including a cooling medium (CM) in contact with at least one of the faces of the concentrator.

Abstract: The present invention concerns a block copolymer having at least one oligo- or polysaccharide block and at least one elastin-like polypeptide block, wherein said block copolymer comprises at least one repetitive unit having the following formula (I): wherein R? is the side chain of a natural or synthetic amino acid other than proline and derivatives thereof.

Abstract: A compound of formula (I) or any of its pharmaceutically acceptable salt for use in the treatment and/or prevention of a RNA virus infection, and a RNA virus infection from group IV or V of the Baltimore classification wherein R3 represents a chlorine atom or a hydrogen atom, R represents a (C1-C4)alkyl group, a (C3-C6)cycloalkyl group, a halogen atom, a (C1-C5)alkoxy group, a —SO2—NRaRb group, a —SO3H group, a —OH group, a —O—SO2—ORc group or a —O—P(?O)—(ORc)(ORd) group, R1 represents (i) a CF3 group, (ii) a (C1-C10)alkyl group, (iii) a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group or (iv) a phenyl group or a naphthyl group, and R2 represents a hydrogen atom, a (C1-C10)alkyl group, a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group and further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.

Abstract: A method for analysing a sample uses a resonant support having a surface on which a plurality of separated photonic crystals extends. At least two crystals are configured to capture the same analyte. A resonance wavelength associated with each crystal varies with an amount of analyte in contact with the crystal. The wavelengths define a resonance spectral band between 200-1500 nm. The transmission/reflection of the light is maximum at an associated resonance wavelength. The method includes: illuminating the support in the resonance spectral band, the intensity of the lamination being variable in band; acquiring a measurement image using an image sensor, the image having different regions-of-interest each optically coupled to a photonic crystal; using a reference image representative of an image acquired by the image sensor, when the support is illuminated in the resonance spectral band in a reference configuration; and comparing the measurement image with the reference image.

Abstract: The present invention relates to variants of Terminal deoxynucleotidyl Transferase (TdT), each of which (i) has an amino acid sequence similarity to SEQ ID NO: 2. 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33 or 35 with corresponding amino acid substitutions, (ii) is capable of synthesizing a nucleic acid fragment without a template and (iii) is capable of incorporating a modified nucleotide into the nucleic acid fragment.